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Background: Preoperative chemoradiotherapy (CRT) followed by surgery is the standard care for locally advanced rectal cancer,
but tumour response to CRT and disease outcome are variable. The current study aimed to investigate the effectiveness of plasma
telomerase reverse transcriptase (TERT) levels in predicting tumour response and clinical outcome.
Methods: 176 rectal cancer patients were included. Plasma samples were collected at baseline (before CRT¼T0), 2 weeks after
CRT was initiated (T1), post-CRT and before surgery (T2), and 4–8 months after surgery (T3) time points. Plasma TERT mRNA levels
and total cell-free RNA were determined using real-time PCR.
Results: Plasma levels of TERT were significantly lower at T2 (Po0.0001) in responders than in non-responders. Post-CRT TERT
levels and the differences between pre- and post-CRT TERT levels independently predicted tumour response, and the prediction
model had an area under curve of 0.80 (95% confidence interval (CI) 0.73–0.87). Multiple analysis demonstrated that patients with
detectable TERT levels at T2 and T3 time points had a risk of disease progression 2.13 (95% CI 1.10–4.11)-fold and 4.55 (95% CI
1.48–13.95)-fold higher, respectively, than those with undetectable plasma TERT levels.
Conclusions: Plasma TERT levels are independent markers of tumour response and are prognostic of disease progression in rectal
cancer patients who undergo neoadjuvant therapy.
The identification of specific, sensitive and non-invasive
approaches that facilitate early diagnosis, predict cancer recurrence
and gauge the effectiveness of cancer therapy is an important target
in oncology. As the dynamic nature of the circulatory system and
its constituents may reflect the host’s pathological status, liquid
biopsies, including analysis of circulating tumour cell-free DNA
and RNA released from tumour cells, are being investigated as
potential sources of non-invasive markers that could facilitate
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formulating early cancer diagnosis, making therapeutic decisions
and monitoring disease progression (Gingras et al, 2015; Lewis
et al, 2015; Alix-Panabie`res and Pantel, 2016).
The circulating mRNAs that encode telomerase reverse transcrip-
tase (TERT) may be of particular interest in this setting. TERT, the
catalytic protein of the telomerase complex that synthetises de novo
telomere sequences using the internal telomerase RNA template (TR),
extends telomeres at the ends of eukaryotic chromosomes, thus
preventing cell senescence and death (Blackburn et al, 2006).
Although TR has broad tissue distribution and is constitutively
present in normal and tumour cells, TERT expression, which is
usually repressed in normal somatic cells and is essential for unlimited
replicative potential, has a critical role in tumour formation and
progression (Hanahan and Weinberg, 2011). Several recent studies
have demonstrated that TERT mRNA level in tumours is an
independent prognostic marker in various types of cancers (Giunco
et al, 2015), including colorectal cancer (Bertorelle et al, 2013, 2014).
Notably, circulating TERT mRNA has been identified in patients with
gastric (Tani et al, 2007; Kang et al, 2013), prostatic (March-Villalba
et al, 2012), lung (Miura et al, 2006), and colorectal cancers (Lledo´
et al, 2004; Terrin et al, 2008). Evidence that circulating TERT mRNA
levels reflect TERT mRNA levels in tumours (Miura et al, 2006;
Terrin et al, 2008; Deblakshmi et al, 2015) supports the concept that
circulating cell-free TERT mRNA may be a promising non-invasive
biomarker in clinical practice.
Worldwide, colorectal cancer is the third most common cancer in
men and the second in women. It accounts for over 9% of all cancers,
with an estimated 1.4 million cases occurring in 2012 (Torre et al,
2016). Approximately 30% of colorectal cancer arise in the rectum
(Siegel et al, 2014) and preoperative chemoradiotherapy (CRT) is the
standard care for locally advanced rectal tumours, but response to
CRT varies from complete to none (Sauer et al, 2004; Bosset et al,
2006; Gerard et al, 2006; Roh et al, 2009). Although the non-
responder patients are exposed to inefficient, toxic therapy, patients
with a pathological complete response to CRT show better outcomes
compared with non-responders (Maas et al, 2010). Although
identifying predictors of tumour response has become crucially
important, biomarkers that are able to predict tumour response to
CRT and foresee disease outcomes are for the time being unavailable
(Spolverato et al, 2011; Lim et al, 2015).
Predicting tumour response to therapy has important clinical
implications, not only for facilitating the selection of patients who will
respond to CRT but also for modifying chemoradiation regimens and
surgical procedures. A prognostic biomarker could also help to
identify patients at higher risk of disease progression or recurrence,
who would benefit from adjuvant therapy and intensive surveillance.
In a retrospective pilot study, conducted in a small group of rectal
cancer patients who underwent CRT followed by surgery, we evaluated
circulating TERT mRNA plasma levels before and after CRT. Study
results showed that TERT levels fell significantly in the responders, but
they remained unvaried or even rose in the non-responders, thus
suggesting that plasma TERT mRNA can be a marker of tumour
response to CRT (Pucciarelli et al, 2012). This result, together with
evidence of the prognostic role of TERT mRNA levels in tumour cells
of patients with colorectal cancer (Bertorelle et al, 2013) and the
finding that circulating TERT levels reflect those in cancer specimens
(Terrin et al, 2008) prompted us to assess the role of circulating TERT
mRNA as a predictive marker of response to neoadjuvant therapy and
a prognostic marker of disease progression in a larger number of
patients with rectal cancer.
PATIENTS AND METHODS
Patients and treatment characteristics. This study was conducted
in patients with primary adenocarcinoma of the rectum, who were
enrolled in a prospective study and underwent CRT followed by
total mesorectal excision at the Surgery Section, Department of
Surgery, Oncology and Gastroenterology, University of Padova (87
patients), and at the Centro di Riferimento Oncologico, Aviano (89
patients). The patients’ work-up included clinical history, physical
examination, colonoscopy, complete blood cell count, pelvic
magnetic resonance imaging, chest/abdomen computed tomogra-
phy scan and carcinoembryonic antigen (CEA) determination. The
criteria for receiving neoadjuvant CRT were as follows: biopsy-
proven adenocarcinoma of the mid–low rectum (up to 11 cm from
the anal verge), clinically staged as Tumour, Node, Metastasis
(TNM) II–III or stage I low-lying rectal cancer requiring
abdominoperineal resection and an Eastern Cooperative Oncology
Group performance status score of 0–2. Patients received a total
dose of radiotherapy X45Gy (median 50.40Gy, range 45–54Gy)
delivered with high-energy photons (X6MV) at conventional
fractionation (1.8 Gy per day, 5 sessions per week) and fluoropyr-
imidine-based chemotherapy.
Peripheral blood samples were drawn from patients at the
study’s time point, that is, at diagnosis, pre-CRT, (T0), 2 weeks
after initiating CRT (T1), post-CRT and before ( 2 to 0 day)
surgery (T2) and 4–8 months after surgery (T3). Plasma samples
were obtained from peripheral blood by centrifugation at
3000 r.p.m. for 10min and aliquots were stored at  80 1C until
they were analysed. Only patients with plasma samples atX3 time
points (134 patients) or plasma samples at least at T0 and T2 time
points (42 patients), for a total of 176 patients, were included in
this study and represent the study group. The local Ethics
Committees approved the study and each patient signed the
informed consent (protocol number 35333/AO/15).
Evaluation of pathologic tumour response. Pathologists from the
institutions involved in the study, unaware of patients’ outcomes,
assessed the surgical specimens. The tumours were pathologically
staged according to the American Joint Committee on Cancer that
established TNM staging system (Edge and Compton, 2010; Amin
et al, 2017). The tumour response to CRT was assessed in surgical
specimens by pathological examination based on Mandard’s
tumour regression grading (TRG) system (Mandard et al, 1994).
Tumour regression grading was defined as follows: no residual
cancer cells¼TRG1; rare residual cancer cells¼TRG2; fibrosis
outgrowing residual cancer cells¼TRG3; residual cancer cells
outgrowing fibrosis¼TRG4; absence of regressive changes¼
TRG5. In accordance with previous studies (Beddy et al, 2008;
Pucciarelli et al, 2012), this classification was further simplified by
considering patients classified as TRG1 and 2 as responders, and
those with TRG 3 to 5 as non-responders.
RNA extraction from plasma samples. RNA was extracted from
plasma samples as previously described (Terrin et al, 2008;
Pucciarelli et al, 2012), with some modifications to improve
RNA extraction. Each plasma sample (500 ml) was slowly thawed
on ice and then mixed with 1500 ml of Trizol LS reagent (Thermo
Fisher Scientific, Waltham, MA, USA) in a 15ml conical tube.
After 5min of incubation at room temperature, 400 ml of
chloroform were added to each sample, followed by 15 s of
shaking and 15min of incubation on ice. The samples were then
centrifuged at 12 000 g for 30min at 4 1C in a J-25 Centrifuge
(Beckman Coulter, Brea, CA, USA). The upper aqueous phase was
transferred into a new 2ml tube, mixed with 1ml of isopropyl
alcohol and 15 ml of Glycogen (5mgml 1, Thermo Fisher
Scientific) and incubated overnight at  20 1C to allow for RNA
precipitation. The samples were then centrifuged at 12 000 g for 1 h
at 4 1C in a microcentrifuge (Biofuge Stratos, Hareaus Instruments,
Thermo Fisher Scientific). The supernatant was removed and the
RNA pellet was washed with 1ml 75% ethanol by centrifugation at
12 000 g for 15min at 4 1C. The ethanol was removed, the RNA
pellet was dried for 5min at room temperature and then
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resuspended in 20 ml of RNase-free water. RNA was reverse-
transcribed into cDNA using the SuperScript TM III RNase reverse
trancriptase assay (Thermo Fisher Scientific) in a final volume of
80 ml, according to the manufacturer’s instructions.
Quantification of circulating TERT mRNA. The expression of
TERT transcripts in the plasma samples was quantified by real-
time PCR, as previously described (Terrin et al, 2008), with some
modifications. In particular, a new primer pair was designed in
order to reduce the length of the amplified product, thus
improving detection of the cDNA target sequence (El-Hefnawy
et al, 2004; Spornraft et al, 2014). Primers AT1 (50-CGGAA-
GAGTGTCTGGAGCAA-30) and AT2b (50-CGCAGCTG-
CACCCTCTTCA-30) were designed on exon 3 and 4,
respectively; they bind to nucleotide sequences located upstream
of the RT motif 1 on the TERT gene allowing amplification of all
TERT transcripts producing an amplified product of 68 bp. The
fluorogenic probe AT (FAM 50-TTGCAAAGCATTGGAATCA-
GACAGCAC-30 TAMRA) recognises the sequence located inside
the product amplified by AT1/AT2b. The PCR was performed
using an ABI prism 7900 Sequence Detection System (PE Applied
Biosystems, Foster City, CA, USA) in 50 ml of mixture containing
25 ml 2X TaqMan Universal (PE Applied Biosystems), 100 nM of
fluorogenic probe, 600 nM of primer AT1, 900 nM of primer AT2b
and 10 ml of cDNA sample. After 2min at 50 1C to allow the uracil
N-glycosylase to act and a denaturation step lasting 10min at
95 1C, 50 cycles were run, each consisting of 30 s at 95 1C, 30 s at
60 1C and 30 s at 72 1C. Each sample was run in triplicate and the
mean Ct values were plotted against the standard TERT reference
curve, which was generated with serial fivefold dilutions of the
TERT amplicon, as previously described (Terrin et al, 2007). TERT
values were estimated per ml according to the X 8 X 2 conversion
factor and then expressed as TERT copies per ml.
Ten microlitres cDNA from each sample were also amplified for
the housekeeping hypoxantin-guanine phosphoribosyl transferase
1 (HPRT1) gene (Terrin et al, 2008; Pucciarelli et al, 2012). The
forward primer HPRT1for (50-TCAGGCAGTATAATCCAAA-
GATGGT-30) was designed between exons 4 and 5, and the
reverse primer HPRT1rev (50-CTTCGTGGGGTCCTTTTCAC-30)
was designed on exon 6, generating a cDNA amplified product of
64 bp. The fluorogenic probe (VIC 50-AAGGTCGCAAGCTT-30
MGBNFQ) recognises the sequence located within the products
amplified by HPRT1for/HPRT1rev. PCR was performed using an
ABI prism 7900 Sequence Detection System (PE Applied
Biosystems) in 50 ml of mixture containing 25ml 2 TaqMan
universal master mix (PE Applied Biosystems), 200 nM of
fluorogenic probe, 900 nM of primer HPRT1for and HPRT1rev
and 10 ml of cDNA sample. The thermal cycler profile consisted of
2min at 50 1C, 10min at 95 1C and then 45 cycles were run, each
consisting of 30 s at 95 1C, 30 s at 60 1C and 30 s at and 72 1C. Each
sample was run in triplicate and the mean Ct values were plotted
against the standard HPRT1 reference curve, prepared using serial
dilutions of the HPRT1 amplicon, as previously described (Terrin
et al, 2008). TERT values were expressed as TERT copies per 103
HPRT1 copies.
Quantification of circulating cell-free RNA. To determine the
amount of cell-free RNA in plasma samples, a calibration weight
standard curve was constructed, as previously described (Terrin
et al, 2008). Briefly, 1 mg of RNA (TaqMan Control Genome RNA
50 ngml 1, Applied Biosystems) was retrotranscribed into cDNA
and fivefold serially diluted in TE buffer (Tris HCl 10mM, pH 7.6,
EDTA 1mM, pH 8.0) from 5000 to 32 pg ml 1. Ten microlitres of
cDNA were collected from each dilution and amplified for the
housekeeping gene HPRT1 with the HPRT1for/HPRT1rev primer
pair. All samples were analysed in triplicate and the resulting
median Ct values were plotted against the calibration weight curve.
The values of cell-free RNA were estimated per ml using the
conversion factor X 8 X 2 and expressed as pgml 1.
Statistical analysis. The data were analysed using SAS 9.4 (SAS
Institute, Cary, NC, USA). The clinical and demographic
characteristics of the rectal cancer patients were described
according to median and interquartile range (IQR) for quantitative
data, and frequencies and percentages for categorical data, and
their relationship with tumour response to neoadjuvant therapy
was assessed using the Kruskal–Wallis test and the w2-test or
Fisher’s exact test, as appropriate.
The distribution of marker (TERT, RNA and CEA) levels
between responder and non-responder groups was assessed at each
time point using the Kruskal–Wallis test and the pairwise
comparisons between each time point within each group was
assessed by the Wilcoxon’s signed-rank test. A receiver operator
characteristic (ROC) curve was constructed to estimate the
specificity and sensitivity of the best cut-off value discriminating
between responders and non-responders. Univariate logistic
regression models were used to evaluate the relationship between
the potential clinical and biological predictors and the tumour
response; variables statistically significant at 10% level were entered
into a multiple logistic model to backward select predictors that
were independently associated with the response to neoadjuvant
therapy. The diagnostic performance of the final multiple model
was estimated with the area under curve (AUC).
The time-to-event analysis by Kaplan–Meier and the univariate
Cox proportional hazard models provided the estimates of the
probability of disease progression. Progression-free survival (PFS)
was calculated from the date of surgery to the occurrence of
relapse/progression or death. Patients who did not develop any
event during the study period were censored at the date of last
observation. The PFS probability was compared among strata
using the log-rank test and the 5-year PFS was reported with the
95% confidence interval (CI). Separate multiple Cox proportional
hazard models were developed with biological markers drawn after
CRT, before surgery (T2), and 4–8 months after surgery (T3),
together with clinical factors resulting significant at univariate
analysis. No deviation from the proportional hazards assumption
was found using the numerical methods of Lin et al (1993). All the
statistical tests used a two-sided 5% significance level and
association measures were provided with their 95% CI.
RESULTS
Demographic and clinical characteristics of patients. The
characteristics of the 176 patients who met the inclusion criteria
are summarised in Supplementary Table 1. According to the
simplified TRG classification, 74 patients (48 TRG1 and 26 TRG2)
were considered responders and 102 patients (74 TRG3, 23 TRG4
and 5 TRG5) were non-responders. The responders were
significantly older (P¼ 0.0106) and had an earlier clinical stage
(P¼ 0.0393) than non-responders. No differences were found in
any of the other baseline characteristics (Supplementary Table 1).
Association between TERT levels and tumour response to
neoadjuvant therapy. Circulating cell-free TERT mRNA (hence-
forth TERT) was determined in 175 patients at T0 and in 153
patients at T2 time point; at T1, samples were available from 117
patients. At T0, TERT levels did not differ between responders and
non-responders: the median (IQR) was 153 (0–325) copies per ml
in responders and 137 (0–350) copies per ml in non-responders
(P¼ 0.472) (Figure 1A). At T1, a fall in TERT levels, although not
significant, was detected in responders, being TERT level 11 (0–
204) copies per ml (P¼ 0.285), but not in non-responders, being
TERT level 132 (0–208) copies per ml (P¼ 0.996). At T2, the
TERT levels were significantly lower in the responders with respect
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those in non-responders (0 (0–40) copies per ml vs 162 (10–283)
copies per ml, Po0.0001) (Figure 1A).
The results obtained when TERT levels were normalised for
HPRT1 were comparable. TERT levels were 90 (0–270), 20 (0–140)
and 0 (0–50) copies per 103 HPRT1 copies at T0, T1 and at T2,
respectively (Po0.0001) in responders, and 80 (0–200), 50 (0–170)
and 90 (10–190) copies per 103 HPRT1 copies at T0, T1 and at T2,
respectively (P¼ 0.814) in non-responders (Figure 1B). At T2, the
difference between the two groups was highly significant (0 (0–50)
copies per 103 HPRT1 copies vs 90 (10–190) copies per 103 HPRT1
copies, Po0.0001)) (Figure 1B).
The differences in the TERT levels between pre- and during
CRT (DT0–T1), during and post-CRT (DT1–T2) and pre- and
post-CRT (DT0–T2) time points in the responders and the non-
responders are outlined in Figure 1C; the differences between the
groups were significant for DT0–T2 (109 (0–241) vs  20 ( 148
to 84) copies per ml, Po0.0001) and DT1-T2 (5 (0–170) vs  12
( 109 to 40) copies per ml, P¼ 0.0011). Similar results were
obtained when TERT levels were normalised for the HPRT1
(Figure 1D).
Notably, total cell-free RNA significantly decreased only in
responders: the estimated levels were 1466 (789–2491) pgml 1,
1066 (515–1824) pgml 1 and 591 (277–1126) pgml 1
(Po0.0001) at T0, T1 and T2, respectively, in responders, and
1669 (960–2448) pgml 1, 1414 (750–2452) pgml 1 and 1689
(756–3068) pgml 1 (P¼ 0.1091) at T0, T1 and T2, respectively, in
non-responders. Although cell-free RNA levels did not differ in the
two groups at T0 (P¼ 0.8607), they were statistically different at
T2 (Po0.0001).
Carcinoembryonic antigen levels were not statistically different
between responders and non-responders, neither pre-CRT
(median (IQR) 1.8 (1.0–3.2) vs 2.2 (1.2–4.08) ngml 1,
P¼ 0.1089) nor post-CRT (median (IQR) 1.6 (1–2.21) vs 1.6
(1.1–2.55) ngml 1, P¼ 0.3355).
Prediction of tumour response to neoadjuvant therapy. Age,
TERT level at T2 and TERT DT0–T2 were found to be significant
predictors of tumour response at univariate analysis and cTNM
tended to be significant (P¼ 0.0591) (Table 1). Notably, the TERT
level at T2 was predictive of response, both with regard to its
median level and its detection (40) or not detection (¼ 0)
(Table 1).
The ROC analysis showed that the TERT value at T2 that best
discriminated between the responders and the non-responders was
90 copies per ml; with this cut-off value, the sensitivity and
specificity of the assay were 91% (95% CI 81–97%) and 67% (95%
CI 56–76%), respectively, with an AUC of 0.78 (95% CI 0.71–0.85)
(Supplementary Figure 1A).
Carcinoembryonic antigen levels significantly decreased in both
responders and non-responders, and CEA levels at both T0 (pre-
CRT) and T2 (post-CRT) time points lacked any predictive value
of tumour response to neoadjuvant therapy with an AUC of 0.57
(36% (95% CI 24–47%) sensitivity, 79% (95% CI 44–66%)
specificity), and 0.55 (44% (95% CI 32–57%) sensitivity, 66%
(95% CI 55–76%) specificity), respectively.
As prediction of tumour response after neoadjuvant therapy
may also have clinical implications (with regard to alternative
approaches to standard surgery, e.g., transanal local excision or
observation), a multiple analysis was performed using factors that
were available before surgery. It was found that TERT levels at T2
time point and TERT DT0–T2 independently predicted tumour
response (Table 2). When the T2 TERT levels were undetectable or
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Figure 1. TERT level in responders and non-responders to neoadjuvant therapy. TERT levels in responder and non-responder patients, pre- (T0),
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below the median level, the OR of tumour response was 7.84 (95%
CI 3.64–16.87, Po0.0001) and 8.32 (95% CI 3.80–18.20,
Po0.0001), respectively (Table 2). The diagnostic performance
of the prediction model, assessed by the ROC curve, had an AUC
of 0.80 (95% CI 0.73–0.87) (Table 2 and Supplementary Figure 1B).
Prognostic value of TERT levels for PFS. TERT levels at T3 (4–8
months after surgery) were available for 102 patients. The pTNM
stage, TRG score and TERT levels at T2 and at T3 time points were
significantly associated with PFS in the univariate analysis
(Table 3). The patients’ PFS curves according circulating plasma
TERT levels are shown in Figure 2. At a median follow-up of 61.2
months, the 5-year PFS of the patients with detectable (40) or
undetectable (¼ 0) T2 TERT levels were 58.8 % (95%CI 47.1–68.7)
and 79.9 % (95% CI 67.8–87.8), respectively (P¼ 0.0008, Table 3
and Figure 2A), and with T2 TERT levels 4 or p median level
were 59.2% (95% CI 47.0–69.4) and 77.6 % (95% CI 65.9–85.7),
respectively (P¼ 0.0030, Table 3 and Figure 2B). The 5-year PFS of
the patients with detectable or undetectable T3 TERT levels were
53.1% (95% CI 37.6–66.3) and 90.6% (95% CI 76.6–96.4),
respectively (Po0.0001, Table 3 and Figure 2C). PFS curves
according to pTNM and TGR scores are shown in Supplementary
Figure 2A and 2B. Notably, the CEA levels after surgery (CEA T3),
but not those before surgery (CEA T2), had a prognostic value
(Table 3 and Supplementary Figure 2C).
The results of multiple logistic regression analysis with
biological markers after CRT and prior surgery (T2), performed
in the 147 patients for whom all data were available, showed that
pTNM and TERT were independent prognostic factors of disease
progression. Multiple analysis of biological markers 4–8 months
after surgery (T3) in the 92 patients for whom all data were
available disclosed that pTNM, TERT and CEA maintained
their independent prognostic role (Table 4). Detection of TERT
at T2 and T3 time points was associated with a risk of disease
progression of 2.13 (95% CI 1.10–4.11)-fold and 4.55 (95% CI
1.48–13.95)-fold higher, respectively, with respect to patients with
undetectable circulating TERT (Table 4).
DISCUSSION
Circulating cell-free nucleic acids constitute minimally invasive
‘liquid biopsies’ that are potentially useful for formulating cancer
diagnosis, monitoring disease progression and guiding therapeutic
decisions (Gingras et al, 2015; Lewis et al, 2015; Alix-Panabie`res
and Pantel, 2016). The finding that TERT is activated in most
tumours has opened new fields in cancer research. The results of
the present study confirm the findings of a previous one showing
Table 1. Univariate logistic regression analysis indicating
associations between covariates of interest and tumour
response to neoadjuvant therapy
Responders/
N % OR 95% CI P-value
Age (years) 1.03 1.00;1.06 0.0478
Gender
Female 25/54 46.3 1.28 0.67;2.45 0.4477
Male 49/122 40.2 1
Distance from anal
verge (cm)
0.94 0.84;1.06 0.3177
Total radiotherapy
dose (Gy)
o50.40 11/24 45.8 1.46 0.54;3.93 0.4564
50.40 39/91 42.9 1.29 0.63;2.64 0.4823
450.40 18/49 36.7 1
Interval between
CRT and surgery
(days)
0.99 0.79;1.25 0.9551
Fluoropyrimidine
Alone 42/94 44.7 1.39 0.73;2.63 0.3133
þother drugs 25/68 36.8 1
No 2/6 33.3 0.86 0.15;5.04 0.8672
cTNM
I–II 15/25 60.0 2.30 0.97;5.47 0.0591
III 58/147 39.5 1
TERT T0
4median 39/87 44.8 1.29 0.71;2.36 0.4066
pmedian 34/88 38.6 1
TERT T1
pmedian 28/59 47.5 1.48 0.71;3.09 0.2985
4median 22/58 37.9 1
TERT DT0–T1
40 21/43 48.8 1.53 0.72;3.29 0.2708
p0 28/73 38.4 1
TERT T2
¼0 48/69 69.6 8.38 4.03;17.41 o0.0001
40 18/84 21.4 1
TERT T2
pmedian 51/77 66.2 7.98 3.82;16.66 o0.0001
4median 15/76 19.7 1
TERT DT0–T2
40 41/70 58.6 3.42 1.74;6.69 0.0003
p0 24/82 29.3 1
CEA T0
pmedian 39/86 45.3 1.22 0.66;2.24 0.5213
4median 34/84 40.5 1
CEA T2
pmedian 35/79 44.3 1.19 0.62;2.29 0.5957
4median 28/70 40.0 1
CEA DT0–T2
p0 24/52 46.1 1.27 0.65;2.51 0.4840
40 39/97 40.2 1
Abbreviations: CEA¼ carcinoembryonic antigen; CI¼ confidence inteval; CRT¼
chemoradiotherapy; cTNM¼ clinical Tumour, Node, Metastasis classification; OR¼odds
ratio; TERT¼ telomerase reverse transcriptase. Notes: Median levels of TERT were 148, 98
and 42 copies per ml at T0, T1 and T2 time point, respectively. Median levels of CEA were
2.0 and 1.6 ngml 1 a T0 and T2 time point, respectively.
Table 2. Multiple logistic regression analysis indicating
associations between covariates of interest and tumour
response to neoadjuvant therapy
OR 95% CI P-value AUC
Model based on TERT detection or no detection at the T2 time
point
Age (years) NS
cTNM I–II NS
III
TERT T2 ¼ 0 7.84 3.64; 16.87 o0.0001 0.79 (95%
40 1 CI: 0.73; 0.86)
TERT DT0-T2 40 2.42 1.13; 5.20 0.0236
p0 1
Model based on TERT4median orpmedian level at the T2 time
point
Age (years) NS
cTNM I–II NS
III
TERT T2 pmedian 8.32 3.80; 18.20 o0.0001 0.80 (95% CI:
4median 1 0.73; 0.87)
TERT DT0-T2 40 2.64 1.23;5.67 0.0130
p0 1
Abbreviations: AUC¼ area under curve; CI¼ confidence interval; cTNM¼ clinical tumour,
node, metastasis classification; NS¼ not significant; OR=odds ratio; TERT¼ telomerase
reverse transcriptase.
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that plasma TERT mRNA can be considered a predictive marker of
tumour response to neoadjuvant therapy in rectal cancer patients
(Pucciarelli et al, 2012) and demonstrate, for the first time to our
knowledge, its prognostic value of disease progression in such
patients.
The expression of TERT is usually absent in non-neoplastic
tissues but inappropriately activated in most tumours; its detection
can thus be considered a specific marker of an ongoing neoplastic
process (Hanahan and Weinberg, 2011). A large number of studies,
including our own (Terrin et al, 2007, Rampazzo et al, 2012;
Bertorelle et al, 2013; Boscolo-Rizzo et al, 2015; Rampazzo et al,
2017), demonstrated that TERT is a prognostic marker of disease
outcome for many types of lymphoid and solid malignancies
(Giunco et al, 2015). In addition, it has been demonstrated that
circulating TERT levels can be detected in the plasma of colorectal
cancer patients (Lledo´ et al, 2004, Terrin et al 2008) and are
significantly correlated with those in tumour specimens (Terrin
et al, 2008), thus suggesting that plasma TERT may be a useful
non-invasive marker for detecting and monitoring the disease.
The neoadjuvant therapy approach followed by mesorectal
excision has become the standard treatment for patients with
locally advanced rectal cancer (NCCN guidelines, 2017); however,
about 20% of patients are overtreated (Sauer et al, 2004). Moreover,
althoughB60% of patients have a moderate-poor response to this
approach, about 20% of patients show a complete pathologic
response, which translates into much better clinical outcomes with
respect to non-responders (Maas et al, 2010). In the last years,
several prospective studies have suggested organ-sparing
approaches for patients with major or complete clinical responses
(Habr-Gama et al, 2004; Belluco et al, 2011; Bujko et al, 2013;
Pucciarelli et al, 2013; Appelt et al, 2015). The advisability of
adjuvant chemotherapy in patients with good response to
neoadjuvant therapy continues to be a subject of debate. Given
these considerations, there is a strong interest to identify
biomarkers that are predictors of tumour response and prognostic
of disease outcome in order to improve selection of those patients
who could benefit from neoadjuvant or adjuvant treatments, who
could avoid surgery altogether or who could be spared unnecessary
and toxic treatment. Unfortunately, although many clinical,
pathological, and molecular markers have been investigated as
predictors of tumour response and prognosis, none of them have
gained wide acceptance in clinical practice (Spolverato et al, 2011;
Lim et al, 2015). Identifying in this scenario circulating biomarkers
predictive of tumour response would be an important step forward
in monitoring these patients in a minimally invasive way.
As demonstrated in a previous study (Pucciarelli et al, 2012), plasma
TERT levels after completion of CRT (time point T2), but not those at
baseline, were strongly predictive of tumour response. The results of the
present study, characterised by a larger number of patients and an
additional time point, that is, during CRT, have confirmed that TERT is
an independent predictive marker and that plasma TERT levels tended
to fall in responders, but not in non-responders soon after CRT is
Table 3. Univariate Cox regression analysis indicating associations between covariates of interest and PFS
Events/N % 5-Years PFS (95% CI) Log-rank P-value HR 95% CI P-value
Age (years) 0.98 0.96;1.01 0.2682
Gender
Male 38/120 31.7 68.4 (59.0;76.2) 0.9901 1
Female 18/54 33.3 67.2 (52.6;78.2) 1.00 0.57;1.76 0.9913
Distance from anal verge (cm) 0.98 0.89;1.09 0.7270
Total radiotherapy dose (Gy)
o50.40 7/24 29.2 67.9 (43.6;83.5) 0.1816 1
50.40 27/91 29.7 71.7 (61.0;79.9) 0.78 0.35;1.80 0.5594
450.40 20/49 40.8 58.5 (42.7;71.3) 1.35 0.57;3.19 0.4962
Fluoropyrimidine
Alone 33/94 35.1 63.2 (52.0;72.5) 0.1460 1.63 0.91;2.94 0.1002
þother drugs 18/68 26.5 76.1 (64.0;84.6) 1
No 3/6 50.0 33.3 (1.4;75.5) 2.55 0.74;8.75 0.1375
pTNM
0–II 27/126 21.4 78.7 (70.1;85.2) o0.0001 1
III–IV 26/39 66.7 35.9 (21.4;50.6) 4.35 2.51;7.54 o0.0001
TRG
Response 15/73 20.5 78.2 (66.3;86.3) 0.0047 1
No response 41/101 40.6 60.0 (49.2;69.1) 2.30 1.27;4.17 0.0060
TERT T2
¼0 13/69 18.8 79.9 (67.8;87.8) 0.0008 1
40 36/83 43.4 58.8 (47.1;68.7) 2.83 1.50;5.34 0.0013
TERT T2
pmedian 16/77 20.8 77.6 (65.9;85.7) 0.0030 1
4median 33/75 44.0 59.2 (47.0;69.4) 2.40 1.32;4.37 0.0040
CEA T2
pmedian 24/79 30.4 67.3 (55.0;76.8) 0.3684 1
4median 16/69 23.2 76.9 (64.5;85.4) 0.75 0.40;1.41 0.3700
TERT T3
¼0¼median 4/52 7.7 90.6 (76.6;96.4) o0.0001 1
40 22/50 44.0 53.1 (37.6;66.3) 7.46 2.56;21.6 0.0002
CEA T3
pmedian 7/61 11.5 86.9 (74.4;93.6) 0.0016 1
4median 20/55 36.4 60.8 (45.7;72.9) 3.65 1.54;8.64 0.0032
Abbreviations: CEA¼ carcinoembryonic antigen; CI¼ confidence interval; HR¼hazard ratio; PFS¼progression-free survival; pTNM¼pathological Tumour, Node, Metastasis classification;
TERT¼ telomerase reverse transcriptase; TRG¼ tumour regression grade. Notes: Median levels of TERT at were 42 copies per ml and 0 copies per ml at T2 and T3 time point, respectively.
Median levels of CEA were 1.6 and 1.5 ngml 1 at T2 and T3 time point, respectively.
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initiated. Multiple analysis showed that of the potential predictors
available before surgery, post-CRT TERT levels and the variation of pre-
post CRT TERT levels were independent predictors, with an AUC 0.80.
Models that combined functional imaging with positron emission
tomography, clinical data and blood biomarkers (CEA, IL-8 and
osteopontin) had an AUC of 0.81 for a complete pathological response,
and the model based on biomarkers only had an AUC of o0.70
(Buijsen et al, 2014). New studies foreseeing additional assessment time
points during CRT and integrating plasma markers (e.g., TERT),
endoscopy, imaging modalities and clinical evaluation could lead to
greater sensitivity and specificity in managing individual patient.
As regards CEA, several studies, most using 5 ngml 1 as cut-
off, have demonstrated that low levels were associated with a
tumour response (Moureau-Zabotto et al, 2011; Tural et al, 2013;
Buijesen et al, 2014). Preoperative CEA levels cannot, however, be
used to stratify treatment strategies as they lack sensitivity and
specificity (Lim et al, 2015). In the present study, neither pre- nor
post-CRT CEA levels were able to predict tumour response to
neoadjuvant therapy. Only 27 patients had at baseline CEA
levels higher than 5 ngml 1; even using this cut-off, no association
was found between CEA levels and tumour response (data not
shown).
Of interest, circulating TERT level were also found to an
independent prognostic marker of disease outcome. Although
pathologic tumour staging is of the utmost importance in rectal
cancer patients, it provides only limited prognostic information
and the risk of disease progression cannot be foreseen, even in
patients at the same tumour stage. This may reflect the molecular
and biological heterogeneity of rectal cancers, and highlight the
need for prognostic markers able to stratify patients.
Plasma TERT levels, to the best of our knowledge, have never
been evaluated as prognostic marker in rectal cancer patients.
Previous studies have indicated that telomerase activity and/or
TERT expression rose along with tumour progression in colorectal
cancer (Mala´ska et al, 2004; Terrin et al, 2008; Rampazzo et al,
2010, Kojima et al, 2011), and it is generally agreed that high levels
of TERT and/or telomerase activity in tumour specimens are
associated with poor prognosis (Bertorelle et al, 2014). Higher
levels of TERT may be able to compensate for the greater
shortening of telomeres, due to high proliferative activity. Beyond
preserving telomere length, TERT might also increase the tumour’s
malignant potential by acting as a growth-promoting and anti-
apoptotic factor (Rampazzo et al, 2012; Saretzki, 2014; Celeghin
et al, 2016). In a series of colorectal cancers (stage I to stage IV),
the plasma TERT levels correlated with those in tumours, both
when expressed as copies per ml and when normalised against
HPRT1 (Terrin et al, 2008). The circulating TERT levels may
reflect those in the corresponding cancer specimens.
In agreement with other data (Mass et al, 2010; Lim et al, 2015),
we observed that patients with a good response to neoadjuvant
therapy also had a better prognosis with respect to non-responder
patients. The prognostic value of TRG was not, however,
confirmed by multiple analysis. In addition, circulating CEA levels
quantified several months after surgery, but not those before
surgery, had an independent prognostic value. Multiple Cox
regression analyses showed that only pathologic staging and
plasma TERT levels were independent prognostic factors both at
surgery and afterwards. This finding is important as TERT level at
the time of surgery could assist in selecting patients who would
benefit from adjuvant chemotherapy.
In conclusion, the results of this study have confirmed that levels
of TERT and their variations pre-post neoadjuvant therapy are
predictive biomarkers of tumour response in rectal cancer patients
who undergo CRT. They also showed that TERT levels before and
1.0
A
C
B
P = 0.0008
P < 0.0001
P = 0.00301.0
0.8
0.6
0.4
0.2
0.0
Pr
og
re
ss
io
n-
fre
e 
su
rv
iva
l
Pr
og
re
ss
io
n-
fre
e 
su
rv
iva
l
Pr
og
re
ss
io
n-
fre
e 
su
rv
iva
l
1.0
0.8
0.6
0.4
0.2
0.0
0.8
0.6
0.4
0.2
0.0
0 20 40 60 80 100 120 0 20
TERT T2 levels  median
TERT T2 levels > median
TERT T2 levels undetectable
TERT T2 levels detectable
TERT T2 levels undetectable
TERT T2 levels detectable
40 60 80 100 120
0 20 40 60 80 100 120
Time (months)
Time (months)
Time (months)
Figure 2. PFS according to TERT level. Kaplan–Meier curves for PFS according to (A) detectable or undetectable TERT T2 level before surgery, (B)
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after surgery are independent prognostic markers of disease outcome.
Further studies, including standardised methods of RNA extraction
and quantification, and standardised assay(s) to quantify TERT, are
important to validate the predictive and prognostic roles of plasma
TERT level, and to ascertain its reliability as a circulating biomarker
to monitor in a minimally invasive way the response to therapy and
the disease outcome in cancer patients.
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